Drug Can Significantly Reduce CV Death and Obesity in Type 2 Diabetes and CVD Patients
Emphagliflozin (EMPA) significantly reduces cardiovascular (CV) death, body weight, and visceral adiposity (VA) in patients with type 2 diabetes and cardiovascular disease (CVD), results of a recent drug trial showed.
The results were presented on June 9, 2017, at the American Diabetes Association’s 77th Scientific Sessions.
_________________________________________________________________________________________
RELATED CONTENT
Study: Can Genetic Factors Predict CV Risk in Type 2 Diabetes Patients?
Obesity Affects Cognition in Type 2 Diabetes Patients
_________________________________________________________________________________________
In the EMPA-REG OUTCOME trial, the researchers examined participants for heterogeneity of the drug’s effects on adiposity by age, sex, and degree of abdominal obesity. The researchers randomly assigned patients with type 2 diabetes and CVD to receive placebo, EMPA, 10 mg daily, or EMPA, 25 mg daily, in addition to standard care.
From baseline to week 164, the researchers assessed changes in body weight and validated markers of VA (i.e.,waist circumference, index of central obesity, and estimated total body fat) across subgroups of age, sex, and baseline waist circumference. A mixed model repeated measures analysis was used to analyze patients who received 1 or more doses of EMPA.
A total of 2333 patients received placebo, 2345 received EMPA, 10 mg, and 2342 received EMPA 25 mg. Mean baseline weight was 191.1 lbs for placebo patients, 189.6 lbs for EMPA 10 mg patients, and 190.7 lbs for EMPA 25 mg patients.
Analysis showed greater weight loss and reduced markers of VA among patients who received EMPA compared with those who received placebo across the majority of age, sex, and abdominal obesity groups, according to the researchers.
“EMPA consistently reduced body weight and markers of VA mostly irrespective of age, sex, or degree of baseline VA,” the researchers concluded. “Further analyses are needed to determine the potential contribution of these changes to the observed CV mortality benefit with EMPA.”
—Christina Vogt
Reference:
Neeland IJ, McGuire DK, Mattheus M, Woerle HJ, Johansen OE, Fitchett D. Effect of empagliflozin (EMPA) on anthropometry and markers of visceral and total adiposity by age, sex, and degree of abdominal obesity in patients with type 2 diabetes (T2D) and cardiovascular disease (CVD): EMPA-REG OUTCOME. Paper presented at: American Diabetes Association’s 77th Scientific Sessions; June 9-13, 2017; San Diego, CA. http://www.abstractsonline.com/pp8/ - !/4297/presentation/10484.